Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12 avr. 2023 07h00 HE
|
Amryt Pharma plc
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
03 avr. 2023 07h00 HE
|
Amryt Pharma plc
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt...
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
22 mars 2023 11h00 HE
|
Amryt Pharma plc
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22, 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq:...
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
16 févr. 2023 07h00 HE
|
Amryt Pharma plc
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 Dublin, Ireland, February 16, 2023 Amryt Pharma...
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
08 janv. 2023 15h00 HE
|
Amryt Pharma plc
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - Transaction expands Chiesi’s rare disease medicine portfolio - All cash acquisition at...
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
05 janv. 2023 07h00 HE
|
Amryt Pharma plc
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (Nasdaq: AMYT), a global, commercial-stage...
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
19 déc. 2022 07h00 HE
|
Amryt Pharma plc
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN, Ireland, and Boston MA, December 19, 2022 Amryt...
European Commission approves Mycapssa® for the treatment of Acromegaly
05 déc. 2022 07h00 HE
|
Amryt Pharma plc
European Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3 trial ...
Amryt Announces New Patent for Mycapssa®
30 nov. 2022 07h00 HE
|
Amryt Pharma plc
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...
Amryt Reports Q3 2022 Financial and Operational Results
03 nov. 2022 07h00 HE
|
Amryt Pharma plc
Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M...